Announcement on Obtaining Drug Registration Certificate
Filed with SSE · · 2 pages · Chinese
Summary by 6ix AI
Yabao Pharmaceutical Group Co. Ltd. has announced the receipt of a drug registration certificate for a new product, 克立硼罗软膏, from the National Medical Products Administration.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Yabao Pharmaceutical Group Co. Ltd. on 6ix
Earlier from Yabao Pharmaceutical
- Announcement on Obtaining Notice of Approval for Drug Clinical Trials of Scopolamine Transdermal Patch
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Convening Performance Briefing for 2025 and Q1 2026
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Election of Employee Representative Director for the 10th Session
Later from Yabao Pharmaceutical
- Announcement on Share Repurchase Plan through Call Auction and the Repurchase Report
- Announcement on Shareholdings of Top 10 Shareholders and Top 10 Shareholders of Unrestricted Shares Concerning Share Repurchase
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Notifying Creditors
- Announcement on the Progress of the Capital Increase in a Wholly-owned Subsidiary and the Completion of Industrial and Commercial Registration Changes
Follow Yabao Pharmaceutical into a list and get an email when it puts out news.
Follow Yabao Pharmaceutical